Authors
Kai-Hsiang Stanley Chen, Yih-Chih Jacinta Kuo, Chang-Yu Jeng, Yan-Siou Dong, Chun-Hwei Tai, Robert Chen
Published in
Movement disorders : official journal of the Movement Disorder Society. Aug 13, 2026. Epub Aug 13, 2026.
Abstract
The long-latency reflex (LLR), particularly LLR II elicited by peripheral stimulation, is considered a transcortical reflex and may reflect cortical-subcortical excitability. Its relevance as a biomarker for subthalamic nucleus deep brain stimulation (STN-DBS) optimization in Parkinson's disease remains unclear.
To examine whether LLR II responses are modulated by STN-DBS stimulation parameters and dopaminergic medication, and to explore the potential mechanisms underlying STN-DBS-related motor improvement.
Thirteen Parkinson's disease patients with STN-DBS underwent median nerve stimulation to assess LLR II, quantified as the peak abductor pollicis brevis electromyography (EMG) response at 50-70 ms, normalized to prestimulus baseline EMG, across different stimulation intensities, contacts, and frequency conditions, including 60 Hz, 130 Hz, and an energy-matched condition. A single DBS pulse was also paired with the cortical N20 response at N20 - 2 ms (T1) or N20 + 10 ms (T2) to assess timing-dependent effects. Sixteen Parkinson's disease patients without DBS were tested in medication-on and -off states. Motor severity was assessed using tested-side Unified Parkinson's Rating Scale Part III (UPDRS III) subscores.
LLR II ratio was higher at 70% and 100% of clinical stimulation intensity than during DBS-off (P = 0.0029 and P = 0.042, respectively). LLR II was higher at the most effective than at the least-effective contact (P = 0.042). The clinically most-effective frequency showed higher LLR II than DBS-off and the least-effective frequency (both P = 0.048). In the single-pulse DBS experiment, LLR II increased only at T2 compared to DBS-off (P = 0.047). No medication-state difference was observed.
LLR II was modulated by clinically effective STN-DBS parameters but was insensitive to dopaminergic medication, supporting its utility as a biomarker of DBS-related sensorimotor circuit modulation, potentially involving the hyperdirect pathway. © 2026 International Parkinson and Movement Disorder Society.
PMID:
42595494
Bibliographic data and abstract were imported from PubMed on 14 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 17
- Comments 0